The U.S. Food and Drug Administration (FDA) has approved a new medicine called Yesafili (aflibercept) for treating four eye conditions that can lead to vision loss. These conditions are wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR). Yesafili is given as an injection into the eye by a doctor. It works by blocking a protein that causes abnormal blood vessel growth and leakage in the retina.
This approval is for adults who have one of these conditions. The medicine is not a cure, but it can help slow vision loss and, in some cases, improve vision. The dosing schedule varies depending on the condition. For most patients, injections are given once a month for the first few months, then less often. For some conditions, the doctor may recommend injections every eight weeks.
Yesafili is similar to other anti-VEGF drugs already on the market, such as Eylea. It offers another choice for patients and doctors. However, the approval does not mean Yesafili is more effective than existing treatments. It is important to remember that every patient is different, and what works for one person may not work for another.
If you have one of these eye conditions, talk to your eye doctor about whether Yesafili might be a good option for you. Your doctor can explain the potential benefits and risks, and help you decide on the best treatment plan. Always follow your doctor's advice and never change your treatment without consulting them.
